000 | 01929 a2200493 4500 | ||
---|---|---|---|
005 | 20250516121300.0 | ||
264 | 0 | _c20130712 | |
008 | 201307s 0 0 eng d | ||
022 | _a1521-009X | ||
024 | 7 |
_a10.1124/dmd.112.049460 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aKudo, Toshiyuki | |
245 | 0 | 0 |
_aAnalysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. _h[electronic resource] |
260 |
_bDrug metabolism and disposition: the biological fate of chemicals _cFeb 2013 |
||
300 |
_a362-71 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aArea Under Curve |
650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xantagonists & inhibitors |
650 | 0 | 4 | _aBiotransformation |
650 | 0 | 4 |
_aCarbamates _xblood |
650 | 0 | 4 | _aComputer Simulation |
650 | 0 | 4 | _aCytochrome P-450 CYP2C8 |
650 | 0 | 4 |
_aCytochrome P-450 CYP3A _xmetabolism |
650 | 0 | 4 | _aCytochrome P-450 CYP3A Inhibitors |
650 | 0 | 4 | _aDrug Interactions |
650 | 0 | 4 |
_aEnzyme Inhibitors _xblood |
650 | 0 | 4 |
_aGemfibrozil _xblood |
650 | 0 | 4 |
_aGlucuronides _xpharmacology |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypoglycemic Agents _xblood |
650 | 0 | 4 |
_aItraconazole _xblood |
650 | 0 | 4 | _aLeast-Squares Analysis |
650 | 0 | 4 |
_aLiver _xdrug effects |
650 | 0 | 4 | _aLiver-Specific Organic Anion Transporter 1 |
650 | 0 | 4 | _aModels, Biological |
650 | 0 | 4 | _aNonlinear Dynamics |
650 | 0 | 4 |
_aOrganic Anion Transporters _xantagonists & inhibitors |
650 | 0 | 4 |
_aPiperidines _xblood |
700 | 1 | _aHisaka, Akihiro | |
700 | 1 | _aSugiyama, Yuichi | |
700 | 1 | _aIto, Kiyomi | |
773 | 0 |
_tDrug metabolism and disposition: the biological fate of chemicals _gvol. 41 _gno. 2 _gp. 362-71 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1124/dmd.112.049460 _zAvailable from publisher's website |
999 |
_c22251940 _d22251940 |